Adaptilens Raises $1.6M in Seed Funding

Adaptilens, a Boston, MA-based company that develops accommodating intraocular lens, raised $1.6m in seed funding.


The round was led by Pillar VC with participation from Accanto Partners.

The company intends to use the funds for the development of an innovative accommodating intraocular lens.

Led by Dr. Liane Clamen, Founder and CEO, Adaptilens is developing an accommodating intraocular lens that mimics the natural human lens so that patients will have excellent near, intermediate, and distance vision without the need for eyeglasses or contact lenses.

While this innovative lens will initially be used for patients with cataracts, the AdaptilensTM could also be used to correct the vision of patients with a variety of refractive errors. For example, the AdaptilensTM could be used for patients with presbyopia, which is the loss of near vision caused by decreased elasticity of the eye’s lens, typically occurring in middle age.



Join the discussion